Research Article

HPV VACCINATION IN NIGERIA: LESSONS AND RECOMMENDATIONS FROM THE SUCCESSES OF HPV VACCINATION IN THE UNITED STATES

Adeola O. Fakolade1*, Abimbola Fapohunda2, Amanda Yad-El Ugboji3, Valentina Ijeoma Akpa4, Moyosore Adegboye5, Oge Ilegbune3
1 Ashtabula Regional Medical Center, Cleveland Clinic Affiliate, USA
2 Behavioral & Community Health Sciences I School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
3 Lakeshore Cancer Center/Foundation for Cancer Care, Lagos, Nigeria
4 Graduate School of Public and International Affairs, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
5 School of Computing and Information Science, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
* Corresponding author: adeola.fakolade@gmail.com
Published: Feb, 2026
DOI: 10.67579/njo.2026.agivs4uc
Pages: 15-28
Views: 474
Downloads: 142

Abstract

Human Papilloma Virus (HPV) is one of the most common sexually transmitted infections (STIs) and has been implicated in many cancers, including cervical cancer. Cervical cancer is primarily caused by persistent infection of various high-risk HPV types, and HPV vaccination is a vital and cost-effective tool in preventing HPV infections, thereby reducing the burden of cervical cancer. The HPV vaccine was first introduced in the United States in 2006, and since the introduction of HPV vaccines in the US, there has been a significant impact on HPV infections and related conditions. In October of 2023, Nigeria rolled out a national HPV vaccination campaign. Before the Nigerian government's HPV vaccination rollout, the knowledge, uptake, and awareness of HPV vaccines were poor. Although the routine HPV vaccination program has increased awareness, this does not automatically translate to increased uptake. In this paper, we explore the history of HPV vaccination in the United States (U.S.), its effects on cervical cancer incidence and mortality, and barriers to the uptake of the vaccine in the U.S. We also identify barriers to HPV vaccine uptake in Nigeria and make recommendations based on the success of the U.S. campaign to maximize the effectiveness of the current vaccine campaign.


Keywords

HPV Vaccination Sexually Transmitted Infections (STIs)

References

  1. Centers for Disease Control and Prevention. Human papillomavirus (HPV) infection [Internet]. 2024 [cited 2024 Jul 13]. Available from: https://www.cdc.gov/hpv/parents/about-hpv.html
  2. Mix JM, Van Dyne EA, Saraiya M, et al. Assessing impact of HPV vaccination on cervical cancer incidence among women aged 15–29 years in the United States, 1999–2017: an ecologic study. Cancer Epidemiol Biomarkers Prev.2021;30(1):30–37.
  3. Omone OM, Kozlovszky M. HPV and cervical cancer screening awareness: a case-control study in Nigeria. In: 2020 IEEE 24th International Conference on Intelligent Engineering Systems (INES). Reykjavik (Iceland): IEEE; 2020 [cited 2024 Jun 24]. p.145–152. Available from: https://ieeexplore.ieee.org/document/9147177/
  4. Mafiana JJ, Dhital S, Halabia M, et al. Barriers to uptake of cervical cancer screening among women in Nigeria: a systematic review. Afr Health Sci. 2022;22(2):295–309.
  5. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  6. John-Akinola YO, Ndikom CM, Oluwasanu MM, et al. Cervical cancer and human papillomavirus vaccine knowledge, utilisation, prevention educational interventions and policy response in Nigeria: a scoping review. Cancer Control. 2022;29:1073274822113301.
  7. Egbon M, Ojo T, Aliyu A, et al. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community. BMC Public Health. 2022;22(1):1611.
  8. Olubodun T, Balogun MR, Odeyemi AK, et al. Barriers and recommendations for a cervical cancer screening program among women in low-resource settings in Lagos, Nigeria: a qualitative study. BMC Public Health. 2022;22(1):1906.
  9. Adewole IF, Benedet JL, Crain BT, Follen M. Evolving a strategic approach to cervical cancer control in Africa. Gynecol Oncol. 2005;99(3 Suppl 1):S209–S212.
  10. Hyacinth HI, Adekeye OA, Ibeh JN, Osoba T. Cervical cancer and Pap smear awareness and utilization of Pap smear test among federal civil servants in north central Nigeria. PLoS One. 2012;7(10):e46583.
  11. Lawson O, Ameyan L, Tukur Z, et al. Cervical cancer screening outcomes in public health facilities in three states in Nigeria. BMC Public Health. 2023;23(1):1688.
  12. Nwobodo H, Ba-Break M. Analysis of the determinants of low cervical cancer screening uptake among Nigerian women. J Public Health Afr. 2015;6(2):484.
  13. Nwankwo KC, Aniebue UU, Aguwa EN, et al. Knowledge, attitudes and practices of cervical cancer screening among urban and rural Nigerian women: a call for education and mass screening. Eur J Cancer Care (Engl). 2011;20(3):362–367.
  14. Ilevbare OE, Adegoke AA, Adelowo CM. Drivers of cervical cancer screening uptake in Ibadan, Nigeria. Heliyon. 2020;6(3):e03645.
  15. Ndikom CM, Ofi BA. Awareness, perception and factors affecting utilization of cervical cancer screening services among women in Ibadan, Nigeria: a qualitative study. Reprod Health. 2012;9:11.
  16. World Health Organization. Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer [Internet]. 2023 [cited 2024 Jul 19]. Available from: https://www.afro.who.int/countries/nigeria/news/nigeria-vaccinate-77-million-girls-against-leading-cause-cervical-cancer
  17. Akanbi OA, Iyanda A, Osundare F, Opaleye OO. Perceptions of Nigerian women about human papilloma virus, cervical cancer, and HPV vaccine. Scientifica (Cairo). 2015;2015:1–4.
  18. Yimer NB, Mohammed MA, Solomon K, et al. Cervical cancer screening uptake in sub-Saharan Africa: a systematic review and meta-analysis. Public Health. 2021;195:105–111.
  19. Brown B, Folayan M. Barriers to uptake of human papilloma virus vaccine in Nigeria: a population in need. Niger Med J. 2015;56(4):301.
  20. Ijadunola KT, Olaniyi OA, Adebimpe WO. Knowledge, attitudes, and practices regarding human papillomavirus vaccination in Nigeria: implications for policy and practice. Afr J Reprod Health. 2020;24(3):47–56.
  21. Tobaiqy M, MacLure K. A systematic review of human papillomavirus vaccination challenges and strategies to enhance uptake. Vaccines (Basel). 2024;12(7):746.
  22. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.
  23. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–304.
  24. Meites E. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68. Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm
  25. Harper DM, DeMars LR. HPV vaccines – a review of the first decade. Gynecol Oncol. 2017;146(1):196–204.
  26. Centers for Disease Control and Prevention. HPV vaccination: what everyone should know [Internet]. 2023 [cited 2024 Jul 14]. Available from: https://www.cdc.gov/vaccines/vpd/hpv/public/index.html
  27. Guo F, Cofie LE, Berenson AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med. 2018;55(2):197–204.
  28. Pingali C. National vaccination coverage among adolescents aged 13–17 years — National Immunization Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71.
  29. Pingali C. Vaccination coverage among adolescents aged 13–17 years — National Immunization Survey–Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72.
  30. Boitano TKL, Ketch PW, Scarinci IC, Huh WK. An update on human papillomavirus vaccination in the United States. Obstet Gynecol. 2023;141(2):324.
  31. McClung NM, Gargano JW, Bennett NM, et al. Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008–2014. Cancer Epidemiol Biomarkers Prev. 2019;28(3):602–609.
  32. Rodriguez AM, Do TQN, Chen L, et al. Human papillomavirus vaccinations at recommended ages: how a middle-school-based educational and vaccination program increased uptake in the Rio Grande Valley. Hum Vaccin Immunother. 2022;18(6):2133315.
  33. Sonawane K, Nyitray AG, Nemutlu GS, et al. Prevalence of human papillomavirus infection by number of vaccine doses among US women. JAMA Netw Open. 2019;2(12):e1918571.
  34. Tabibi T, Barnes JM, Shah A, et al. Human papillomavirus vaccination and trends in cervical cancer incidence and mortality in the US. JAMA Pediatr. 2022;176(3):313–316.
  35. Centers for Disease Control and Prevention. HPV-IMPACT Monitoring Project [Internet]. 2023 [cited 2024 Jul 14]. Available from: https://www.cdc.gov/ncird/surveillance/hpvimpact/index.html
  36. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health. 2012;21(10):1031–1037.
  37. National Cancer Institute. Cancer of the cervix uteri – cancer stat facts [Internet]. 2024 [cited 2024 Jul 14]. Available from: https://seer.cancer.gov/statfacts/html/cervix.html
  38. Alhazmi H, AlDukhail S. Disparities in HPV and the HPV vaccine knowledge among non-Hispanic Black adults in the US – HINTS 2017–2020. J Immigr Minor Health. 2024;26(1):117–123.
  39. Elam-Evans LD. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69.
  40. Spencer JC, Calo WA, Brewer NT. Disparities and reverse disparities in HPV vaccination: a systematic review and meta-analysis. Prev Med. 2019;123:197–203.
  41. Chido-Amajuoyi OG, Jackson I, Yu R, Shete S. Declining awareness of HPV and HPV vaccine within the general US population. Hum Vaccin Immunother. 2021;17(2):420–427.
  42. Blake KD, Ottenbacher AJ, Rutten LJF, et al. Predictors of human papillomavirus awareness and knowledge in 2013. Am J Prev Med. 2015;48(4):402–410.
  43. Adjei Boakye E, Tobo BB, Rojek RP, et al. Approaching a decade since HPV vaccine licensure: racial and gender disparities in knowledge and awareness of HPV and HPV vaccine. Hum Vaccin Immunother. 2017;13(11):2713–2722.
  44. Wisk LE, Allchin A, Witt WP. Disparities in human papillomavirus vaccine awareness among US parents of preadolescents and adolescents. Sex Transm Dis. 2014;41(2):117–122.
  45. Anuforo B, McGee-Avila JK, Toler L, et al. Disparities in HPV vaccine knowledge and adolescent HPV vaccine uptake by parental nativity among diverse multiethnic parents in New Jersey. BMC Public Health. 2022;22(1):195.
  46. Mansfield LN, Onsomu EO, Merwin E, et al. Association between parental HPV knowledge and intentions to have their daughters vaccinated. West J Nurs Res. 2018;40(4):481–501.
  47. Zimet GD, Rosberger Z, Fisher WA, et al. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. Prev Med. 2013;57(5):414–418.
  48. Vanderpool RC, Dressler EVM, Stradtman LR, et al. Fatalistic beliefs and completion of the HPV vaccination series among a sample of young Appalachian Kentucky women. J Rural Health. 2015;31(2):199–205.
  49. Teoh D, Hill EK, Goldsberry W, et al. Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.: a Society of Gynecologic Oncology review. Gynecol Oncol. 2018;161(1):228–235.
  50. Moya EM, Garcia A, Ponder AJ, et al. Addressing knowledge gaps: the key role of community health workers and healthcare providers in human papillomavirus prevention and vaccine uptake in a border community. Front Public Health. 2023;11:1243539.
  51. Kong WY, Bustamante G, Pallotto IK, et al. Disparities in healthcare providers' recommendation of HPV vaccination for US adolescents: a systematic review. Cancer Epidemiol Biomarkers Prev. 2021;30(11):1981–1992.
  52. Downs LS, Scarinci I, Einstein MH, et al. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol. 2010;117(3):486–490.
  53. Rani U, Darabaner E, Seserman M, et al. Public education interventions and uptake of human papillomavirus vaccine: a systematic review. J Public Health Manag Pract. 2022;28(1):E307–E315.
  54. Constable C, Ferguson K, Nicholson J, et al. Clinician communication strategies associated with increased uptake of the human papillomavirus (HPV) vaccine: a systematic review. CA Cancer J Clin. 2022;72(6):561–569.
  55. Wu CF, Highfield L, Swint JM, et al. Provider-based HPV vaccine promotion interventions: a meta-analysis. Pediatrics. 2023;151(5):e2022058029.
  56. President's Cancer Panel. HPV vaccination for cancer prevention: progress, opportunities, and a renewed call to action. Report to the President of the United States. 2018.
  57. President's Cancer Panel. Accelerating HPV vaccine uptake: urgency for action to prevent cancer [Internet]. 2014 [cited 2025 Jan 22]. Available from: https://deainfo.nci.nih.gov/Advisory/pcp/annualReports/HPV/index.htm
  58. Lu PJ, Yankey D, Fredua B, et al. National and state-specific estimates of settings of receiving HPV vaccination among adolescents in the United States. J Adolesc Health. 2021;69(4):597–603.
  59. Okolie EA, Nwadike BI. Spotlight on human papillomavirus vaccination coverage: Is Nigeria making any progress? JCO Glob Oncol. 2023;(9):e2300088.
  60. Adesina KT, Saka A, Isiaka-Lawal SA, et al. Knowledge, practice and acceptability of HPV vaccine by mothers of adolescent girls in Ilorin, Nigeria. Sudan J Med Sci. 2018;13(1):33–49.
  61. Ndikom CM, Oboh PI. Perception, acceptance and uptake of human papillomavirus vaccine among female adolescents in selected secondary schools in Ibadan, Nigeria. Afr J Biomed Res. 2017;20(3):237–244.
  62. Okunowo AA, Ugwu AO, Kuku JO, et al. Predictors, barriers and motivating factors for human papillomavirus vaccination and testing as preventative measures for cervical cancer: a study of urban women in Lagos, Nigeria. Prev Med Rep. 2021;24:101643.
  63. Perlman S, Wamai RG, Bain PA, et al. Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review. PLoS One. 2014;9(3):e90912.
  64. Ezenwa BN, Balogun MR, Okafor IP. Mothers' human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Womens Health. 2013;5:371–377.
  65. Kutz JM, Rausche P, Gheit T, et al. Barriers and facilitators of HPV vaccination in sub-Saharan Africa: a systematic review. BMC Public Health. 2023;23(1):974.
  66. Talabi O, Gilbert H, Fawzi MCS, et al. Examining barriers and facilitators of HPV vaccination in Nigeria, in the context of an innovative delivery model: a mixed-methods study. BMJ Public Health. 2023;1(1):e000003.
  67. Nguyen N, Okeke E, Anglemyer A, et al. Identifying perceived barriers to human papillomavirus vaccination as a preventative strategy for cervical cancer in Nigeria. Ann Glob Health. 2020;86:118.
  68. Welcome MO. The Nigerian health care system: need for integrating adequate medical intelligence and surveillance systems. J Pharm Bioallied Sci. 2011;3(4):470–478.
  69. Abubakar I, Dalglish SL, Angell B, et al. The Lancet Nigeria Commission: investing in health and the future of the nation. Lancet. 2022;399(10330):1155–1200.
  70. Ogundeji YK, Tinuoye O, Bharali I, et al. Is Nigeria on course to achieve universal health coverage in the context of its epidemiological and financing transition? BMJ Open. 2023;13(3):e064710.
  71. Ophori EA, Tula MY, Azih AV, et al. Current trends of immunization in Nigeria: prospect and challenges. Trop Med Health. 2014;42(2):67–75.
  72. Rodrigues CMC, Plotkin SA. Impact of vaccines: health, economic and social perspectives. Front Microbiol. 2020;11:1526.
  73. Adejuyigbe FF, Balogun MR, Sekoni AO, et al. Cervical cancer and human papilloma virus knowledge and acceptance of vaccination among medical students in southwest Nigeria. Afr J Reprod Health. 2015;19(1):140–148.
  74. Azuogu BN, Umeokonkwo CD, Azuogu VC, et al. Appraisal of willingness to vaccinate daughters with human papilloma virus vaccine and cervical cancer screening uptake among mothers of adolescent students in Abakaliki, Nigeria. Niger J Clin Pract. 2019;22(9):1286–1291.
  75. Nkwonta CA, Hilfinger Messias DK, Felder T, et al. Increasing human papillomavirus vaccination and cervical cancer screening in Nigeria: an assessment of community-based educational interventions. Int Q Community Health Educ. 2020;41(1):89–99.
  76. Cooper S, Gadanya MA, Kaawa-Mafigiri D, et al. Using social media to build confidence in vaccines: lessons from community engagement and social science research in Africa. BMJ. 2024;384:e075564.
  77. Underwood T, Hopkins KL, Sommers T, et al. Shaping global vaccine acceptance with localized knowledge: a report from the inaugural VARN2022 conference. BMC Proc. 2023;17(Suppl 7):26.
  78. Sadoh AE, Okonkwo C, Nwaneri DU, et al. Effect of peer education on knowledge of human papilloma virus and cervical cancer among female adolescent students in Benin City, Nigeria. Ann Glob Health. 2018;84(1):121–128.
  79. Figueiredo A de, Simas C, Karafillakis E, et al. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396(10255):898–908.
  80. Morhason-Bello IO, Adesina OA, Adedokun BO, et al. Knowledge of the human papilloma virus vaccines, and opinions of gynaecologists on its implementation in Nigeria. Afr J Reprod Health. 2013;17(2):150–156.
  81. Okolie EA, Barker D, Nnyanzi LA, et al. Factors influencing cervical cancer screening practice among female health workers in Nigeria: a systematic review. Cancer Rep. 2022;5(5):e1514.
  82. Smulian EA, Mitchell KR, Stokley S. Interventions to increase HPV vaccination coverage: a systematic review. Hum Vaccin Immunother. 2016;12(6):1566–1588.
  83. Morgan C, Giattas MR, Holroyd T, et al. Integration of other services with human papillomavirus vaccination: lessons from earlier in the life course highlight the need for new policy and implementation evidence. Vaccine. 2022;40:A94–A99.
  84. Walling EB, Benzoni N, Dornfeld J, et al. Interventions to improve HPV vaccine uptake: a systematic review. Pediatrics. 2016;138(1):e20153863.
How to Cite

Fakolade, A. O., Fapohunda, A., Ugboji, A. Y., Akpa, V. I., Adegboye, M., & Ilegbune, O. (2026). HPV VACCINATION IN NIGERIA: LESSONS AND RECOMMENDATIONS FROM THE SUCCESSES OF HPV VACCINATION IN THE UNITED STATES. Nigerian Journal of Oncology, 2(1), 15-28. https://doi.org/10.67579/njo.2026.agivs4uc

A. O. Fakolade, A. Fapohunda, A. Y. Ugboji, V. I. Akpa, M. Adegboye, and O. Ilegbune, "HPV VACCINATION IN NIGERIA: LESSONS AND RECOMMENDATIONS FROM THE SUCCESSES OF HPV VACCINATION IN THE UNITED STATES," Nigerian Journal of Oncology, vol. 2, no. 1, pp. 15-28, February 2026. doi: 10.67579/njo.2026.agivs4uc

Share this article:
Facebook X / Twitter LinkedIn
Download PDF View Full Text (PDF) Back to Articles